Horizon Therapeutics Public Limited Company G46188101 IE00BQPVQZ61 07/27/2023 Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in this Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 6450.000000 0 AGAINST 6450.000000 AGAINST Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 08/03/2023 To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 2700.000000 0 FOR 2700.000000 FOR Medtronic plc G5960L103 IE00BTN1Y115 10/19/2023 Approving, on an advisory basis, the Company's executive compensation; SECTION 14A SAY-ON-PAY VOTES 40051.000000 0 FOR 40051.000000 FOR Mirati Therapeutics, Inc. 60468T105 US60468T1051 12/13/2023 To approve, by non-binding, advisory vote, compensation that may be paid or become payable by Mirati to its named executive officers in connection with the Merger. SECTION 14A SAY-ON-PAY VOTES 4133.000000 0 AGAINST 4133.000000 AGAINST ImmunoGen, Inc. 45253H101 US45253H1014 01/31/2024 A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to ImmunoGen's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement; and SECTION 14A SAY-ON-PAY VOTES 11038.000000 0 AGAINST 11038.000000 AGAINST Karuna Therapeutics, Inc. 48576A100 US48576A1007 03/12/2024 To approve, on an advisory, non-binding basis, certain compensation that will or may be paid by Karuna to its named executive officers that is based on or otherwise relates to the merger of Merger Sub with and into Karuna pursuant to the merger agreement. SECTION 14A SAY-ON-PAY VOTES 1480.000000 0 FOR 1480.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/14/2024 Advisory Vote to Approve Executive Compensation. SECTION 14A SAY-ON-PAY VOTES 5500.000000 0 FOR 5500.000000 FOR IQVIA Holdings Inc. 46266C105 US46266C1053 04/16/2024 Approve an advisory (non-binding) resolution to approve IQVIA's executive compensation (say-on-pay). SECTION 14A SAY-ON-PAY VOTES 16600.000000 0 FOR 16600.000000 FOR Humana Inc. 444859102 US4448591028 04/18/2024 Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2024 proxy statement. SECTION 14A SAY-ON-PAY VOTES 8225.000000 0 FOR 8225.000000 FOR Inari Medical, Inc. 45332Y109 US45332Y1091 04/24/2024 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 38000.000000 0 FOR 38000.000000 FOR Halozyme Therapeutics, Inc. 40637H109 US40637H1095 04/25/2024 To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 3900.000000 0 FOR 3900.000000 FOR Johnson & Johnson 478160104 US4781601046 04/25/2024 Advisory Vote to Approve Named Executive Officer Compensation SECTION 14A SAY-ON-PAY VOTES 53850.000000 0 FOR 53850.000000 FOR Pfizer Inc. 717081103 US7170811035 04/25/2024 2024 advisory approval of executive compensation SECTION 14A SAY-ON-PAY VOTES 189400.000000 0 FOR 189400.000000 FOR Abbott Laboratories 002824100 US0028241000 04/26/2024 Say on Pay - An Advisory Vote on the Approval of Executive Compensation SECTION 14A SAY-ON-PAY VOTES 72248.000000 0 FOR 72248.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/02/2024 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 91476.000000 0 FOR 91476.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Say on Pay - An advisory vote on the approval of executive compensation SECTION 14A SAY-ON-PAY VOTES 35200.000000 0 FOR 35200.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/03/2024 Say on Pay - An advisory vote on the frequency of the advisory vote to approve executive compensation SECTION 14A SAY-ON-PAY VOTES 35200.000000 0 ONE YEAR 35200.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/06/2024 Approval, on an advisory basis, of the compensation paid to the company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 24465.000000 0 FOR 24465.000000 FOR Moderna, Inc. 60770K107 US60770K1079 05/06/2024 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 10400.000000 0 FOR 10400.000000 FOR Danaher Corporation 235851102 US2358511028 05/07/2024 To approve on an advisory basis the Company's named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 18725.000000 0 FOR 18725.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/07/2024 Advisory Vote to Approve Named Executive Officer Compensation SECTION 14A SAY-ON-PAY VOTES 15650.000000 0 FOR 15650.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/08/2024 To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 27000.000000 0 FOR 27000.000000 FOR Stryker Corporation 863667101 US8636671013 05/09/2024 Advisory Vote to Approve Named Executive Officer Compensation. SECTION 14A SAY-ON-PAY VOTES 6600.000000 0 FOR 6600.000000 FOR Zimmer Biomet Holdings, Inc. 98956P102 US98956P1021 05/10/2024 Approve, on a non-binding advisory basis, named executive officer compensation ("Say on Pay"). SECTION 14A SAY-ON-PAY VOTES 29750.000000 0 FOR 29750.000000 FOR Insmed Incorporated 457669307 US4576693075 05/13/2024 An advisory vote on the 2023 compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 11721.000000 0 FOR 11721.000000 FOR Centene Corporation 15135B101 US15135B1017 05/14/2024 ADVISORY RESOLUTION TO APPROVE EXECUTIVE COMPENSATION. SECTION 14A SAY-ON-PAY VOTES 34000.000000 0 FOR 34000.000000 FOR Cytokinetics, Incorporated 23282W605 US23282W6057 05/15/2024 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 33250.000000 0 FOR 33250.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/15/2024 Advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 3500.000000 0 FOR 3500.000000 FOR Option Care Health, Inc. 68404L201 US68404L2016 05/15/2024 To approve, on a non-binding advisory basis, our executive compensation. SECTION 14A SAY-ON-PAY VOTES 64000.000000 0 FOR 64000.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/15/2024 Advisory vote to approve named executive office compensation. SECTION 14A SAY-ON-PAY VOTES 5419.000000 0 FOR 5419.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/16/2024 To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. SECTION 14A SAY-ON-PAY VOTES 16500.000000 0 FOR 16500.000000 FOR Illumina, Inc. 452327109 US4523271090 05/16/2024 To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 4370.000000 0 FOR 4370.000000 FOR Medpace Holdings, Inc. 58506Q109 US58506Q1094 05/17/2024 To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2024 Annual Meeting. SECTION 14A SAY-ON-PAY VOTES 910.000000 0 FOR 910.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/21/2024 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 46500.000000 0 FOR 46500.000000 FOR DexCom, Inc. 252131107 US2521311074 05/22/2024 To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2023. SECTION 14A SAY-ON-PAY VOTES 33400.000000 0 FOR 33400.000000 FOR Insulet Corporation 45784P101 US45784P1012 05/22/2024 To approve, on a non-binding, advisory basis, the compensation of certain executive officers. SECTION 14A SAY-ON-PAY VOTES 18100.000000 0 FOR 18100.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/22/2024 Advisory vote on the compensation paid to the Company's named executive officers; SECTION 14A SAY-ON-PAY VOTES 2950.000000 0 FOR 2950.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/22/2024 An advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 10515.000000 0 FOR 10515.000000 FOR Progyny, Inc. 74340E103 US74340E1038 05/23/2024 Approval, on an advisory (non-binding) basis, of the compensation of the company's named executive officers SECTION 14A SAY-ON-PAY VOTES 76000.000000 0 FOR 76000.000000 FOR Verastem, Inc. 92337C203 US92337C2035 05/23/2024 To approve an advisory vote on the compensation of the named executive officers. SECTION 14A SAY-ON-PAY VOTES 67500.000000 0 FOR 67500.000000 FOR Verastem, Inc. 92337C203 US92337C2035 05/23/2024 Advisory vote on the frequency of future advisory votes on the compensation of our named executive officers SECTION 14A SAY-ON-PAY VOTES 67500.000000 0 ONE YEAR 67500.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/28/2024 Non-binding advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 86500.000000 0 FOR 86500.000000 FOR Arvinas, Inc. 04335A105 US04335A1051 05/29/2024 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 46100.000000 0 FOR 46100.000000 FOR Exelixis, Inc. 30161Q104 US30161Q1040 05/30/2024 To approve, on an advisory basis, the compensation of Exelixis' named executive officers, as disclosed in the accompanying Proxy Statement SECTION 14A SAY-ON-PAY VOTES 9300.000000 0 FOR 9300.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 10050.000000 0 FOR 10050.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/31/2024 To approve, in a non-binding, advisory vote, the frequency of future advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 10050.000000 0 ONE YEAR 10050.000000 FOR Amgen Inc. 031162100 US0311621009 05/31/2024 Advisory vote to approve our executive compensation. SECTION 14A SAY-ON-PAY VOTES 13050.000000 0 FOR 13050.000000 FOR Denali Therapeutics Inc. 24823R105 US24823R1059 05/31/2024 Advisory vote on executive compensation SECTION 14A SAY-ON-PAY VOTES 8500.000000 0 FOR 8500.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/03/2024 Advisory approval of the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES 23175.000000 0 FOR 23175.000000 FOR Apellis Pharmaceuticals, Inc. 03753U106 US03753U1060 06/05/2024 Approval of an advisory vote on executive compensation; and SECTION 14A SAY-ON-PAY VOTES 7150.000000 0 FOR 7150.000000 FOR BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 15 - Ordinary Resolution THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved. SECTION 14A SAY-ON-PAY VOTES 3060.000000 0 AGAINST 3060.000000 AGAINST BeiGene, Ltd. 07725L102 US07725L1026 06/05/2024 Resolution 16 - Ordinary Resolution THAT, on a non-binding, advisory basis, the frequency of future advisory votes on the compensation of the Company's named executive officers will be held at the frequency hereby approved. SECTION 14A SAY-ON-PAY VOTES 3060.000000 0 ONE YEAR 3060.000000 FOR Cogent Biosciences, Inc. 19240Q201 US19240Q2012 06/05/2024 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 255400.000000 0 FOR 255400.000000 FOR Cogent Biosciences, Inc. 19240Q201 US19240Q2012 06/05/2024 Advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 255400.000000 0 ONE YEAR 255400.000000 FOR MoonLake Immunotherapeutics 61559X104 KY61559X1045 06/05/2024 Approval of, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 44804.000000 0 FOR 44804.000000 FOR MoonLake Immunotherapeutics 61559X104 KY61559X1045 06/05/2024 Non-binding advisory vote on the frequency of future advisory votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES 44804.000000 0 ONE YEAR 44804.000000 FOR Amicus Therapeutics, Inc. 03152W109 US03152W1099 06/06/2024 Approval, on an advisory basis, the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES 210869.000000 0 FOR 210869.000000 FOR Arcus Biosciences, Inc. 03969F109 US03969F1093 06/06/2024 To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 89725.000000 0 FOR 89725.000000 FOR GoodRx Holdings, Inc. 38246G108 US38246G1085 06/06/2024 Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 356000.000000 0 FOR 356000.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/06/2024 To make an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES 7200.000000 0 FOR 7200.000000 FOR Royalty Pharma Plc G7709Q104 GB00BMVP7Y09 06/06/2024 A non-binding advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES 13500.000000 0 FOR 13500.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/06/2024 advisory vote to approve, on a non-binding basis, name executive officer compensation SECTION 14A SAY-ON-PAY VOTES 15710.000000 0 FOR 15710.000000 FOR Vaxcyte, Inc. 92243G108 US92243G1085 06/06/2024 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 6250.000000 0 FOR 6250.000000 FOR Alphatec Holdings, Inc. 02081G201 US02081G2012 06/12/2024 To approve, on an advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 136000.000000 0 FOR 136000.000000 FOR Blueprint Medicines Corporation 09627Y109 US09627Y1091 06/12/2024 Approval of a non-binding advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES 3150.000000 0 ONE YEAR 3150.000000 FOR Blueprint Medicines Corporation 09627Y109 US09627Y1091 06/12/2024 Approval of a non-binding advisory vote on the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES 3150.000000 0 FOR 3150.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/12/2024 Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 6680.000000 0 FOR 6680.000000 FOR Intellia Therapeutics, Inc. 45826J105 US45826J1051 06/12/2024 Approve, on a non-binding advisory basis, the compensation of the named executive officers. SECTION 14A SAY-ON-PAY VOTES 6200.000000 0 FOR 6200.000000 FOR Olema Pharmaceuticals, Inc. 68062P106 US68062P1066 06/13/2024 Approval, on an advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 134450.000000 0 FOR 134450.000000 FOR Rocket Pharmaceuticals, Inc 77313F106 US77313F1066 06/13/2024 Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis. SECTION 14A SAY-ON-PAY VOTES 10500.000000 0 FOR 10500.000000 FOR Intra-Cellular Therapies, Inc. 46116X101 US46116X1019 06/14/2024 To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 4900.000000 0 FOR 4900.000000 FOR Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/14/2024 Proposal to approve, on an advisory basis, executive compensation. SECTION 14A SAY-ON-PAY VOTES 6000.000000 0 FOR 6000.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/14/2024 Approval, by a non-binding advisory vote, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 165000.000000 0 FOR 165000.000000 FOR Zai Lab Limited 98887Q104 US98887Q1040 06/18/2024 THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved. SECTION 14A SAY-ON-PAY VOTES 2000.000000 0 AGAINST 2000.000000 AGAINST Biogen Inc. 09062X103 US09062X1037 06/20/2024 Say on Pay - To hold an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES 4902.000000 0 FOR 4902.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/20/2024 To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES 51758.000000 0 FOR 51758.000000 FOR Revolution Medicines, Inc. 76155X100 US76155X1000 06/20/2024 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES 9100.000000 0 FOR 9100.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/21/2024 To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 11500.000000 0 FOR 11500.000000 FOR Madrigal Pharmaceuticals, Inc. 558868105 US5588681057 06/25/2024 Advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES 800.000000 0 FOR 800.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2024 Advisory resolution to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES 1365.000000 0 FOR 1365.000000 FOR Scholar Rock Holding Corporation 80706P103 US80706P1030 06/27/2024 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 10900.000000 0 FOR 10900.000000 FOR Scholar Rock Holding Corporation 80706P103 US80706P1030 06/27/2024 To approve, on a non-binding, advisory basis, the preferred frequency of future advisory votes on compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 10900.000000 0 ONE YEAR 10900.000000 FOR